| 17-May-13 01:04PM | OSIRIS THERAPEUTICS, INC. Financials EDGAR Online Financials +6.32% |
| 16-May-13 01:30PM | Pipeline Progress at Gilead Zacks |
| 10-May-13 01:03AM | OSIRIS THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 09-May-13 08:16PM | Is the Golden Age of Blockbusters Over? at Motley Fool |
| 08-May-13 05:55PM | Osiris Loss In-Line with Expectations Zacks |
| 07-May-13 03:28PM | Safe Stem Cell Therapy for Healing Is Still a Strong Bet at Motley Fool |
| 02:30PM | Osiris Therapeutics Management Discusses Q1 2013 Results - Earnings Call Transcript at Seeking Alpha |
| 02:22PM | Osiris Therapeutics price target raised to $14 from $11.50 at Piper Jaffray theflyonthewall.com |
| 01:19PM | Osiris CEO: Our Stem Cell Drug With Zero Sales Is Widely Used at TheStreet |
| 08:00AM | Osiris Therapeutics Announces First Quarter 2013 Financial Results Business Wire |
| 07:07AM | Q1 2013 OSIRIS THERAPEUTICS INC Earnings Release - Before Market Open CCBN |
| 01:01AM | OSIRIS THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and EDGAR Online |
| 03-May-13 04:00PM | Loss at Aegerion Narrower Than Expected Zacks |
| 02-May-13 04:06PM | Athersys Has Some Promise, But Controversy And Doubt Remain at Seeking Alpha |
| 01-May-13 11:22AM | Convenience is Key in Cell Therapy Products: An Expert Analyst Discusses His Coverage of the Oncology and Cell Therapy Spaces with The Wall Street Transcript Wall Street Transcript -9.27% |
| 08:22AM | Vertex Loss Lower, Kalydeco Outlook Up Zacks |
| 30-Apr-13 03:20PM | Double Setback for Gilead Zacks |
| 29-Apr-13 09:20AM | Geron Narrows Loss; Cuts Jobs Zacks |
| 07:00AM | Osiris Therapeutics to Present at the 12th Annual Needham Healthcare Conference Business Wire |
| 25-Apr-13 05:00PM | Osiris Therapeutics Announces First Quarter 2013 Financial Results Conference Call Business Wire |
| 11:00AM | Biogen's Earnings Surpass Expectations Zacks |
| 22-Apr-13 11:40AM | Sanofi's Vaccine Gets EU Approval Zacks |
| 19-Apr-13 02:10PM | Vertex CF Candidate Impresses Zacks +5.28% |
| 15-Apr-13 01:20PM | Affymetrix Down to Underperform Zacks |
| 11-Apr-13 04:40PM | Alkermes Announces Restructuring Plan Zacks |
| 08:36AM | The Vatican's Pontifical Council for Culture, NeoStem, The Stem for Life Foundation & STOQ International Host 2nd International Vatican Adult Stem Cell Conference GlobeNewswire |
| 10-Apr-13 08:10AM | Affymetrix to Disappoint in 1Q Zacks +5.34% |
| 04:00AM | The Vatican / NeoStem Partnership Looks To Create Interest And Advance Cell Therapy at Seeking Alpha |
| 09-Apr-13 05:25PM | Patients Dosed in Arena Study Zacks |
| 03:35PM | Sanofi Unveils Bond Issue Pricing Zacks |
| 08-Apr-13 05:25PM | ISIS Initiates ISIS-APOA Study Zacks |
| 05-Apr-13 01:58PM | Glaxo Eyes Benlysta Label Expansion Zacks |
| 08:21AM | Zacks Industry Outlook Highlights: Eli Lilly, Novo Nordisk, Biogen, Amgen and Osiris Therapeutics Zacks |
| 04-Apr-13 04:08PM | AstraZeneca Takes Over AlphaCore Zacks |
| 03-Apr-13 07:58AM | Perrigo Touches 52-Week High Zacks |
| 02-Apr-13 04:13PM | Perrigo Buys Velcera Zacks |
| 09:18AM | Celgene Reaches 52-Week High Zacks |
| 01-Apr-13 04:23PM | Gilead's HCV Study to Continue Zacks |
| 28-Mar-13 05:00AM | Osiris Therapeutics Inc. Stock Upgraded (OSIR) at TheStreet |
| 26-Mar-13 03:28PM | Acorda Reports Data on Epilepsy Drug Zacks |
| 09:18AM | CHMP Negative on Gentium Candidate Zacks |
| 09:01AM | Opexa: A Significant Growth Opportunity For Short-Term Traders And Long-Term Investors at Seeking Alpha |
| 25-Mar-13 06:08PM | Gilead's Stribild Backed by CHMP Zacks |
| 24-Mar-13 08:00AM | Last Week's Best- And Worst-Performing Medical Stocks at Forbes |
| 20-Mar-13 01:04PM | OSIRIS THERAPEUTICS, INC. Financials EDGAR Online Financials |
| 19-Mar-13 05:43PM | SGEN Seeks Adcetris Label Expansion Zacks +9.17% |
| 04:38PM | AstraZeneca to Revamp R&D Structure Zacks |
| 09:15AM | Cell Therapy Leader Stephen Potter Talks Osiris, NeoStem And The Industry Itself at Seeking Alpha |
| 18-Mar-13 04:08PM | Theravance Inks Deal for Vibativ Zacks |
| 15-Mar-13 03:43PM | BioLineRx to Initiate HCV Study Zacks |
| 01:28PM | Alexion Pharma Upgraded to Outperform Zacks |
| 08:05AM | OSIRIS THERAPEUTICS, INC. Files SEC form 10-K, Annual Report EDGAR Online |
| 14-Mar-13 11:31AM | Lower Loss at Geron Zacks |
| 07:52AM | Zacks Bull and Bear of the Day Highlights: Cincinnati Financial, ArcelorMittal, Biogen, Sanofi and Osiris Therapeutics Zacks |
| 07:00AM | Osiris Therapeutics to Present at the Canaccord Genuity Musculoskeletal Conference Business Wire |
| 13-Mar-13 04:48PM | Peregrine Reports Narrower Loss Zacks |
| 03:43PM | Biogen Files Hemophilia B Application Zacks |
| 12-Mar-13 05:48PM | Major Setback for Aeterna Zentaris Zacks |
| 11-Mar-13 02:25PM | 4 Stocks Spiking on Unusual Volume at TheStreet +6.39% |
| 09-Mar-13 05:45AM | 3 Humongous Health-Care Stocks This Week at Motley Fool |
| 08-Mar-13 04:54PM | Osiris Wows The Market With Stellar Earnings Report at Seeking Alpha |
| 03:43PM | Acorda Presents GGF2 Data Zacks |
| 06:00AM | Biotech Stock Mailbag: Celldex, TG Therapeutics, Sarepta at TheStreet |
| 04:00AM | Osiris Therapeutics Inc. Stock Downgraded (OSIR) at TheStreet |
| 07-Mar-13 07:27PM | New Star Analyst Rankings for Osiris Therapeutics, Inc. StarMine |
| 06:03PM | Nasdaq stocks posting largest percentage increases AP |
| 01:16PM | Nasdaq stocks posting largest percentage increases AP |
| 08:20AM | Biotech Industry Soars in 2012 as FDA Drug Approvals Reach a 15-Year High Marketwire |
| 07:58AM | Narrower-Than-Expected Loss at OSIR Zacks |
| 01:44AM | Osiris Therapeutics: A Few Things To Consider As Earnings Trump Estimates at Seeking Alpha |
| 06-Mar-13 07:33PM | Osiris keeps losses down, investors reward shares at MarketWatch +35.31% |
| 06:12PM | Osiris keeps losses down, investors reward shares at MarketWatch |
| 06:05PM | Nasdaq stocks posting largest percentage increases AP |
| 01:17PM | Nasdaq stocks posting largest percentage increases AP |
| 12:43PM | Endeavour International, Osiris Therapeutics: Biggest Price Gainers (END, OSIR) at The Wall Street Journal |
| 12:30PM | Osiris Therapeutics Management Discusses Q4 2012 Results - Earnings Call Transcript at Seeking Alpha |
| 12:20PM | Osiris keeps losses down, investors reward shares at MarketWatch |
| 10:57AM | Osiris Therapeutics upgraded to Overweight from Neutral at Piper Jaffray theflyonthewall.com |
| 10:44AM | Osiris shares jump on higher 4Q revenue report AP |
| 08:01AM | OSIRIS THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and EDGAR Online |
| 08:00AM | Osiris Therapeutics Reports Fourth Quarter and Full Year 2012 Financial Results Business Wire |
| 07:07AM | Q4 2012 OSIRIS THERAPEUTICS INC Earnings Release - Before Market Open CCBN |
| 01-Mar-13 07:30AM | Osiris Therapeutics Establishes Direct Sales Force for Grafix® Business Wire +7.75% |
| 28-Feb-13 02:15PM | 2012 Stem Cell Standouts And The Outlook For 2013 at Seeking Alpha |
| 27-Feb-13 09:40AM | Acute Radiation Syndrome, Are We Prepared And Who Is Best Preparing Us? at Seeking Alpha |
| 22-Feb-13 05:00PM | Osiris Therapeutics Announces Fourth Quarter and Full Year 2012 Financial Results Conference Call Business Wire |
| 20-Feb-13 04:12PM | Osiris Therapeutics On The Brink: Products Failing To Deliver at Seeking Alpha |
| 19-Feb-13 04:11PM | Osiris Rises on European Stem-Cell Drug Title Decision at Bloomberg +8.97% |
| 01:59PM | Osiris Rises on European Stem-Cell Drug Title Decision at Bloomberg |
| 07:07AM | InPlay: Osiris Therapeutics receives title of european orphan drug designation for Prochymal Briefing.com |
| 07:00AM | Osiris Therapeutics Receives Title of European Orphan Drug Designation for Prochymal® Business Wire |
| 18-Feb-13 07:05PM | Osiris Therapeutics Successfully Defends Key Stem Cell Patent Challenge Business Wire |
| 13-Feb-13 03:36PM | 2 Regenerative Medicine Plays For 2013 at Seeking Alpha |
| 09-Jan-13 06:35AM | Stem Cell Companies For Consideration In 2013 at Seeking Alpha |
| 07-Jan-13 09:13AM | 2012 Breakthroughs In Cell Therapy Development at Seeking Alpha |
| 02-Jan-13 10:28AM | With Osiris Overvalued, NeoStem Is A Better Buy at Seeking Alpha |
| 21-Dec-12 02:18PM | Cell Therapy Might Be Poised For A Comeback at Investor's Business Daily |
| 13-Dec-12 09:35AM | Mid-Week Biopharma Catalyst Trades To Consider at Seeking Alpha |
| 29-Nov-12 02:56PM | Are Short-Sellers Onto Something at Pluristem Therapeutics? at Motley Fool |
| 27-Nov-12 05:59PM | Orphan Status Update from Pluristem Zacks |
